PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCopper oxodotreotide cu-64
Copper oxodotreotide cu-64
Copper oxodotreotide cu-64 is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
detectnetNew Drug Application2025-01-31
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuroendocrine tumorsD018358EFO_1001901D3A.82221310
NeoplasmsD009369—C801——113
Pancreatic neoplasmsD010190EFO_0003860C25———112
Stomach neoplasmsD013274EFO_0003897C16———112
Intestinal neoplasmsD007414—C26.0———112
Islet cell adenomaD007516EFO_0007331D13.7———1—1
Indications Phases 3
No data
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PheochromocytomaD010673———1——12
ParagangliomaD010235———1——12
Neuroendocrine carcinomaD018278———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Prostatic neoplasmsD011471—C611————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SarcoidosisD012507EFO_0000690D80-D89————22
Gastrointestinal neoplasmsD005770—C26.9————11
Digestive system neoplasmsD004067——————11
Gastrointestinal diseasesD005767——————11
Germ cell and embryonal neoplasmsD009373——————11
Endocrine system diseasesD004700EFO_0001379E34.9————11
Neoplasms by histologic typeD009370——————11
Endocrine gland neoplasmsD004701EFO_0003769D35————11
Neoplasms by siteD009371——————11
Nerve tissue neoplasmsD009380——————11
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCopper oxodotreotide cu-64
INN_
Description
Copper oxodotreotide cu-64 is a protein pharmaceutical. It is currently being investigated in clinical studies.
Classification
Protein
Drug classpeptides: inhibition of growth hormone release
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL4297339
ChEBI ID—
PubChem CID—
DrugBank—
UNII IDN3858377KC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 134 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
37 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use